GW501516 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
In nuclear physics, transient equilibrium is a situation in which equilibrium is reached by a parent-daughter radioactive isotope pair where the half-life of the daughter is shorter than the half-life of the parent. Contrary to secular equilibrium, the half-life of the daughter is not negligible compared to parent's half-life. An example of this is a molybdenum-99 generator producing technetium-99 for nuclear medicine diagnostic procedures. Such a generator is sometimes called a cow because the daughter product, in this case technetium-99, is milked at regular intervals. Transient equilibrium occurs after four half-lives, on average.
(2026) report fossil evidence from the Pyvykha Mountain site (Ukraine) indicative of coexistence of archaeocetes of at least two different body size categories in the same locality during the middle Eocene, and interpret the studied cetaceans as likely to be close relatives of the ancestors of Neoceti. Van Rompaey et al. (2026) describe fossil material of Brevirostrodelphis aff. dividum and Brevirostrodelphis sp. from the Berchem Formation (Belgium), providing evidence of presence of members of this genus in the North Sea Basin and their trans-Atlantic distribution during the Miocene, and reinterpret the type specimen of Phocaenopsis sheynensis as a specimen of Kentriodon sp. The first porpoise fossil material from the western North Atlantic is reported from the Pliocene strata near Charleston (South Carolina, United States) by Kofranek et al. (2026). Tanaka et al. (2026) report the first discovery of fossil material of a toothed whale from the Miocene (Burdigalian to Langhian) strata of the Korematsu Formation (Japan). Buchholtz et al. (2026) report evidence of links between sternal shape and feeding behaviors in extant baleen whales, and reconstruct the transition from raptorial predation to filter feeding during the evolutionary history of baleen whales on the basis of the study of sternal morphology in extinct members of the group. Strauch & Pyenson (2026) report the discovery of fossil material of cf. Salishicetus from the Oligocene or Miocene strata of the Vaqueros Formation (California, United States).
==== The 12 nidanas in Mahāyāna sutras and tantras ==== Alex Wayman writes that Mahāyāna texts such as Śrīmālādevī Siṃhanāda Sūtra present an alternative interpretation of the twelve nidanas. According to Wayman, this interpretation holds that arhats, pratyekabuddhas, and bodhisattvas have eliminated the four kinds of clinging (nidana # 9), which are the usual condition for existence (or "gestation", nidana #10) and rebirth (#11) in one of the three realms. Instead of being reborn, they have a "body made of mind" (manōmaya kāya), which is a special consciousness (vijñana). This consciousness is projected by ignorance (nidana #1) and purified by a special kind of samskara (# 2) called "nonfluxional karma" (anāsrava-karma). These mind-made bodies produce a reflected image in the three worlds, and thus they appear to be born. According to Wayman, this view of dependent origination posits "a dualistic structure of the world, in the manner of heaven and earth, where the "body made of mind" is in heaven and its reflected image, or coarser equivalent, is on earth. Otherwise stated, the early members of Dependent Origination apply to the superior realm, the later members to the inferior realm. But the Śrī-mālā-Sūtra does not clarify how those members are allotted to their respective realms." According to Wayman, similar interpretations appear in tantric texts, such as the Caṇḍamahāroṣaṇatantra.
=== Perioperative medicine === Clonidine is sometimes used in perioperative medicine as an adjunctive therapy during the perioperative period, where it is administered alongside other analgesics to provide sedation and pain-control. Whilst clonidine itself has limited clinical utility as a monotherapy for postoperative pain, its combination with opioid medications may allow adequate pain relief to be achieved at lower opioid doses, which may reduce the frequency and severity of opioid-related adverse effects. Compared with other sedative and opioid medications used perioperatively, clonidine does not produce respiratory depression or anterograde amnesia. Moreover, its hemodynamic-stabilising effects and ability to reduce postoperative shivering are considered particularly useful in patients at high risk of myocardial ischaemia. Clonidine also has anxiolytic properties that may help reduce preoperative anxiety. In perioperative settings, clonidine may be orally ingested during the preoperative stage or administered intravenously or intramuscularly immediately before, during or shortly after surgery. Clonidine can also be administered via epidural or intrathecal catheters as an adjuvant to local anesthetics to enhance perioperative and postoperative neuraxial blockade. Clonidine's analgesic effects are attributed in part to activation of α2 adrenoreceptors within the dorsal horn of the spinal cord, which inhibits the release of pronociceptive neurotransmitters from primary afferent terminals and hyperpolarizes nociceptive interneurons.
Sources: en.wikipedia.org
=== Signs and symptoms === The classic clinical syndrome for vitamin B6 deficiency is a seborrheic dermatitis-like eruption, atrophic glossitis with ulceration, angular cheilitis, conjunctivitis, intertrigo, abnormal electroencephalograms, microcytic anemia (due to impaired heme synthesis), and neurological symptoms of somnolence, confusion, depression, and neuropathy (due to impaired sphingosine synthesis). In infants, a deficiency in vitamin B6 can lead to irritability, abnormally acute hearing, and convulsive seizures. Less severe cases present with metabolic disease associated with insufficient activity of the coenzyme pyridoxal 5' phosphate (PLP). The most prominent of the lesions is due to impaired tryptophan–niacin conversion. This can be detected based on urinary excretion of xanthurenic acid after an oral tryptophan load. Vitamin B6 deficiency can also result in impaired transsulfuration of methionine to cysteine. The PLP-dependent transaminases and glycogen phosphorylase provide the vitamin with its role in gluconeogenesis, so deprivation of vitamin B6 results in impaired glucose tolerance.
A polyhistidine-tag, best known by the trademarked name His-tag, is an amino acid motif in proteins that typically consists of at least six histidine (His) residues, often at the N- or C-terminus of the protein. It is also known as a hexa histidine-tag, 6xHis-tag, or His6 tag. The tag was invented by Roche, although the use of histidines and its vectors are distributed by Qiagen. Various purification kits for histidine-tagged proteins are commercially available from multiple companies. The total number of histidine residues may vary in the tag from as low as two, to as high as 10 or more His residues. N- or C-terminal His-tags may also be followed or preceded, respectively, by a suitable amino acid sequence that facilitates removal of the polyhistidine-tag using endopeptidases. This extra sequence is not necessary if exopeptidases are used to remove N-terminal His-tags (e.g., Qiagen TAGZyme). Furthermore, exopeptidase cleavage may solve the unspecific cleavage observed when using endoprotease-based tag removal. Polyhistidine-tags are often used for affinity purification of genetically modified proteins.
==== Eye Caps ==== Eye caps are used when setting the facial features to close the eyes. They are plastic and dome-shaped with sharp protrusions on the convex surface to help shape the eyes and keep them closed. Similarly, mouth formers are used to help shape the mouth. They are usually applied when there are no teeth to shape the lips.
In 1769, William Cullen called attention to diabetic urine that was "insipid" in taste:I myself, indeed, think I have met with one instance of diabetes in which the urine was perfectly insipid; and it would seem that a like observation had occurred to Dr. Martin Lister. I am persuaded, however, that such instances are very rare; and that the other is much more common and perhaps the almost universal occurrence. I judge therefore, that the presence of such a saccharine matter may be considered as the principal circumstance in idiopathic diabetes.In 1788, Thomas Cawley published a case study in the London Medical Journal based on an autopsy of a diabetic patient. He suggested a link between the pancreas and diabetes after observing stones and signs of tissue damage in the patient's pancreas. The significance of this discovery went unappreciated for another hundred years. In 1794, Johann Peter Frank of the University of Pavia found that his patients were characterized by "long continued abnormally increased secretion of non-saccharine urine which is not caused by a diseased condition of the kidneys". He introduced the term insipidus, derived from the Latin ('tasteless'). Frank is often credited as the first physician to describe clinical differences between diabetes mellitus and diabetes insipidus. This claim, however, warrants further examination given prior instances of comparable description (e.g. those by William Cullen). It has been noted that 1792 seems to be the year when "unequivocal" diabetes insipidus was first described in the medical literature.
It is very important to quickly cool the wort to a level where yeast can be added safely as yeast is unable to grow in very high temperatures, and will start to die in temperatures above 60 °C (140 °F). After the wort goes through the heat exchanger, the cooled wort goes into a fermentation tank. A type of yeast is selected and added, or "pitched", to the fermentation tank. When the yeast is added to the wort, the fermenting process begins, where the sugars turn into alcohol, carbon dioxide and other components. When the fermentation is complete the brewer may rack the beer into a new tank, called a conditioning tank. Conditioning of the beer is the process in which the beer ages, the flavour becomes smoother, and flavours that are unwanted dissipate. After conditioning for a week to several months, the beer may be filtered and force carbonated for bottling, or fined in the cask.
Sources: en.wikipedia.org
=== Kraft Foods === Starbucks and Kraft Foods entered into a partnership in 1998 to sell Starbucks products in the Mondelez grocery stores owned by the latter. Starbucks claimed that Kraft did not sufficiently promote its products and offered Kraft US$750 million to terminate the agreement; however, Kraft declined the offer, but Starbucks proceeded with the termination anyway. Starbucks wanted to terminate the agreement because at the time, single coffee packs were beginning to become popular. In their agreement, Starbucks was confined to selling packs that only worked in Kraft's Tassimo machines. Starbucks did not want to fall behind in the market opportunities for K-Cups. In mid-November 2013, an arbitrator ordered Starbucks to pay a fine of US$2.8 billion to Mondelez International, a corporate spin-off of Kraft, for its premature unilateral termination of the agreement.
Iron plays a certain role in mythology and has found various usage as a metaphor and in folklore. The Greek poet Hesiod's Works and Days (lines 109–201) lists different ages of man named after metals like gold, silver, bronze and iron to account for successive ages of humanity. The Iron Age was closely related with Rome, and in Ovid's Metamorphoses
Alan H. B. Wu is an American clinical chemist, toxicologist, professor, and author. He is known for his work in laboratory medicine, particularly in clinical chemistry, cardiac biomarkers, pharmacogenomics, and clinical toxicology. He is a professor of Laboratory Medicine at the University of California, San Francisco (UCSF), and Chief of Clinical Chemistry and Toxicology and Co-Core Lab Director at the Zuckerberg San Francisco General Hospital.
== Early life == Kleinman was born into a family that valued nature, often gardening, fishing, and hiking. Kleinman's father was a trained geologist and would collect rocks and arrowheads on hikes, which sparked Kleinman's interest in chemical and biological sciences.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.